If you liked this article you might like

Gilead, Pfizer, AbbVie Win From Lilly's Loss
Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views
Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis
Why Biotech Investors Should Worry When Their Stocks Turn Boring